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Background and purpose — Currently, Propionibacterium is fre-
quently recognized as a causative microorganism of prosthetic 
joint infection (PJI). We assessed treatment success at 1- and 
2-year follow-up after treatment of Propionibacterium-associated 
PJI of the shoulder, hip, and knee. Furthermore, we attempted 
to determine whether postoperative treatment with rifampicin is 
favorable.
Patients and methods — We conducted a retrospective cohort 
study in which we included patients with a primary or revision 
joint arthroplasty of the shoulder, hip, or knee who were diag-
nosed with a Propionibacterium-associated PJI between Novem-
ber 2008 and February 2013 and who had been followed up for 
at least 1 year. 
Results — We identified 60 patients with a Propionibacterium-
associated PJI with a median duration of 21 (0.1–49) months until 
the occurrence of treatment failure. 39 patients received rifam-
picin combination therapy, with a success rate of 93% (95% CI: 
83–97) after 1 year and 86% (CI: 71–93) after 2 years. The success 
rate was similar in patients who were treated with rifampicin and 
those who were not.
Interpretation — Propionibacterium-associated PJI treated with 
surgery in combination with long-term antibiotic administration 
had a successful outcome at 1- and 2-year follow-up irrespective 
of whether the patient was treated with rifampicin. Prospective 
studies are needed to determine whether the use of rifampicin is 
beneficial in the treatment of Propionibacterium-associated PJI. 

A prosthetic joint infection (PJI) occurs in 1.5–3% of cases 
after primary joint arthroplasty (Ong et al. 2009, Kurtz et al. 
2010, Singh et al. 2012), whereas the risk of PJI after revi-
sion arthroplasty is even higher (Phillips et al. 2003). Propi-
onibacterium is involved in about 10% of cases, and is a more 
common causative organism of PJI in shoulder arthroplasty 
than in other joint arthroplasties (Levy et al. 2008, Corvec 
et al. 2012). In recent years, the number of Propionibacte-
rium-associated PJIs has been increasing (Bjerke-Kroll et al. 
2014), probably due to improved diagnostic modalities such 
as prolonged cultivation time of tissue cultures and the use of 
implant sonication (Achermann et al. 2014).
Propionibacterium is a gram-positive, relatively slow-grow-
ing microaerophilic rod that is known to be a major colonizer 
and inhabitant of the human skin, especially the sebaceous 
glands. It is recognized to be an important opportunistic patho-
gen causing implant-associated infection, including PJI, due 
to its ability to form biofilms (Ramage et al. 2003, Bayston 
et al. 2007a). Propionibacterium causes a delayed, low-grade 
infection that usually occurs 3–24 months or more after joint 
replacement surgery (Levy et al. 2008, Piper et al. 2009, Singh 
et al. 2012). Distinguishing PJI with Propionibacterium from 
aseptic failure can be difficult due to subtle clinical signs and 
symptoms, such as implant loosening or persistent pain (Zim-
merli et al. 2004, Zappe et al. 2008). 
In general, treatment of a PJI involves surgery involving 
debridement with retention of the prosthesis, 1- or 2-stage 
exchange arthroplasty, resection arthroplasty, arthrodesis, or 
amputation followed by prolonged antibiotic treatment (Zim-
merli et al. 2004). For the treatment of Propionibacterium-
associated PJI, the present clinical practice guidelines of the 
Infectious Diseases Society of America (IDSA) recommend 
monotherapy with either penicillin G, ceftriaxone, clindamy-
cin, or vancomycin (Osmon et al. 2013). Taking into account 
the established effectiveness of rifampicin in staphylococ-
cal PJI (Zimmerli et al. 1998, Baldoni et al. 2009, John et al. 
2009, El Helou et al. 2010) and the few clinical studies dem-
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onstrating positive outcomes of Propionibacterium-associated 
PJI treated with an antimicrobial regimen including rifampi-
cin (Zeller et al. 2007, Levy et al. 2008), combination therapy 
with rifampicin may be favorable in treating Propionibacte-
rium-associated PJI.
We assessed treatment success at 1- and 2-year follow-up after 
treatment of Propionibacterium-associated PJI of the shoulder, 
hip, and knee. We also attempted to determine whether postop-
erative antibiotic treatment with rifampicin is favorable in the 
treatment of Propionibacterium-associated PJI.
Patients and methods
Patients
All intraoperative tissue cultures that were positive for Pro-
pionibacterium, taken between November 2008 and April 
2013 at the Department of Orthopaedic Surgery in Sint 
Maartenskliniek, the Netherlands, were reviewed to retrospec-
tively identify patients with a Propionibacterium-associated 
PJI after primary or revision joint arthroplasty of the shoulder, 
hip, or knee who had been treated with surgery and antibiot-
ics. Patients were included if at least 2 intraoperative tissue 
cultures had been positive for the same Propionibacterium 
strain, antimicrobial treatment had been given, and there had 
been a minimal follow-up time of 1 year after final treatment. 
Demographic, clinical, laboratory, microbiological, and thera-
peutic data were collected from the patients’ medical records. 
Patients were excluded if the inclusion criteria were not met or 
if their medical records were not available. 
Microbiological methods
Periprosthetic tissue samples (5–10 per patient) were cultured 
both aerobically and anaerobically for 10 days at 35°C on 
chocolate and MacConkey agar plates with 5% sheep blood, 
and in thioglycollate medium. On direct plates, Propioni-
bacterium acnes grew within 3-4 days. Thioglycollate was 
incubated for at least 4 days before subcultures where done 
on the same primary plates. In general, a final positive result 
for Propionibacterium acnes was reported within a week. All 
microorganisms were routinely identified with MALDI-TOF 
(Bruker Daltronics, Bremen, Germany). 
Propionibacterium acnes was also tested for catalase, 
indole, and nitrate reductase. Antibacterial susceptibility test-
ing of penicillin, clindamycin, and rifampicin was done with 
E test strips (bioMerieux, Marcy l’Etoile, France) using a 
MacFarland 1 inoculum, incubated anaerobically for 48–72 
h and interpreted according to EUCAST for penicillin and 
clindamycin (http://www.eucast.org/clinical_breakpoints/). 
There are no breakpoints set for rifampicin.
Treatment
In all patients, treatment consisted of surgery and a 3-month 
postoperative antimicrobial regimen. The choice of surgi-
cal procedure was determined by the preoperative diagno-
sis, based on anamnesis, physical examination, radiological 
data, C-reactive protein (CRP), erythrocyte sedimentation 
rate (ESR), white blood cell (WBC) count, and in some cases 
a sterile arthrocentesis. 4 types of PJI were defined accord-
ing to the classification by Tsukayama et al. (1996): an early 
postoperative infection (< 1 month after index surgery), a late 
chronic infection (≥ 1 month after index surgery), an acute 
hematogenous infection (antecedent bacteremia with acute 
onset of symptoms in affected joint with the prosthesis), and 
infection diagnosed from positive intraoperative cultures (≥ 2 
positive cultures of the same specimen obtained at the time of 
revision operation). 
An open debridement and prosthesis retention was per-
formed if an early postoperative or acute hematogenous PJI 
was diagnosed. Those patients with a late chronic infection 
were managed with a 2-stage exchange arthroplasty. Patients 
who, preoperatively, were not suspected of having an infection, 
e.g. with aseptic loosening, polyethylene wear, instability, or 
prosthesis dysfunction, were treated with a 1-stage exchange 
arthroplasty. In these patients, a PJI was therefore diagnosed 
from positive intraoperative cultures. Antibiotic treatment with 
cefazoline (1,000 mg three times a day intravenously (i.v.)) 
was started intraoperatively after taking tissue cultures, and 
was continued for 5 days or until the results of the tissue cul-
tures were available. A switch in antimicrobial treatment took 
place, guided by the positive cultures, and was continued in all 
patients orally (p.o.) or i.v. for a period of 3 months postop-
eratively. We identified 2 antimicrobial treatment groups, those 
with and without additional rifampicin. Whether a patient 
received additional rifampicin depended on the personal pref-
erence of the treating physician. Side effects of the antimicro-
bial treatment were extracted from the medical records. 
Success of treatment
Failure of the retained and replaced prosthesis after finishing 
antimicrobial treatment was defined as a relapse, reinfection, 
and/or removal of the prosthesis for any reason. A relapse was 
defined as positive cultures yielding the same microorganism 
as the initial intraoperative samples. A reinfection was defined 
as a new infection with another pathogen. 
Statistics
Differences in patient characteristics in the 2 treatment groups 
were analyzed with Pearson’s chi-square test or Fisher’s exact 
test when appropriate for categorical data, and the independent 
t-test was used for continuous data. We checked for assump-
tions of continuous data and the homogeneity of variance was 
fulfilled (Levene’s test, p > 0.05). To determine the cumulative 
probability of treatment failure, we performed a Kaplan-Meier 
analysis with 95% confidence intervals. A relapse, reinfection, 
or removal of the prosthesis for any reason was defined as the 
endpoint. Patients who had their implant and no signs of infec-
tion at the end of the study period—or who had died during 
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acute infection consisting of redness, purulent drainage, or 
persistent wound leakage. The intraoperative cultures showed 
a polymicrobial infection in 3 patients (2 hips and 1 knee), and 
a monomicrobial infection in 1 patient with Propionibacte-
rium acnes after primary shoulder arthroplasty. All 4 patients 
were treated with debridement and prosthesis retention, and 
with antibiotics for 3 months. 3 of them received additional 
rifampicin. A reinfection occurred in 1 patient who was not 
treated with rifampicin combination therapy. 
Preoperatively, the remaining patients (a majority) were 
not suspected of having infection and were diagnosed with 
a Propionibacterium-associated PJI from positive intraop-
erative tissue cultures (41/60). Preoperatively, these patients 
mainly complained of having pain, joint stiffness, and insta-
bility. In all 41 patients, the intraoperative cultures showed a 
monomicrobial infection with Propionibacterium acnes. They 
were managed with a one-stage revision arthroplasty followed 
by an antibiotic regimen for 3 months. 25 of the 41 patients 
received rifampicin combination therapy. At last follow-up, 4 
failures had occurred—2 relapse and 2 reinfections (3 in the 
group treated with rifampicin and 1 in the group treated with-
out rifampicin). 
Table 1. Patient characteristics of 60 patients with Propionibacterium-associated 
PJI, presented according to their postoperative antimicrobial treatment
Characteristic Rifampicin No rifampicin Total group p-value
 (n = 39) (n = 21) (n = 60) 
Location of joint, n    1.0
 Knee 15    9  24 
 Hip 12    6  18  
 Shoulder 12    6  18  
Type of arthroplasty, n    
 Primary/revision 31/8 15/6 46/14   
Age at PJI diagnosis a  69 (40–78) 69 (47–80) 69 (40–80) 0.5
Sex, female/male 22/17 7/14 29/31 0.09
BMI, kg/m2 a 28 (21–50) 28 (22–35) 28 (21–50) 0.2
Medical history of PJI, n   2    2   4 0.6
 Missing data   6   0   6 
Clinical presentation, n 
 Missing data   1   0   1 
 Joint pain 31 18 49  1.0
 Stiffness 15 10 25  0.5
 Tumor   9   7 16  0.4
 Instability   7   8 15  0.1
 Rubor   5   1   6  0.4
 Sinus tract   2   2   4  0.6
 Calor   2   1   3  1.0
 Fever   1   1   2  1.0
 Wound leakage   1   1   2  1.0
Laboratory diagnostics    
 ESR > 30 mm/h 12   6 18 0.5
    Missing ESR data   5   3   8 
 CRP > 10 mg/L  10   6 16 0.6
    Missing CRP data   8   7 15 
 Leucocytes, × 109/L a 7.9 (5.2–15) 7.5 (4.9–13) 7.7 (4.9–15) 0.6
    Missing data, n 13 10 23 
Microbiological diagnostics    
 No. of tissue cultures a  7 (6–9) 6 (5–10) 6 (5–10) 0.3
 No. of positive cultures a  3 (2–9) 3 (2–7) 3 (2–9) 0.8
 Mono/polymicrobial 28/11 19/2 47/13 0.1
PJI classification b    0.7
 Early postoperative   3   1   4  
 Late chronic   9   4 13  
 Acute hematogenous   2   0   2 
 Positive intraoperative cultures 25 16 41 
PJI: periprosthetic joint infection; BMI: body mass index; 
ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.
a Values are median (range)
b According to Tsukayama et al. (1996): early postoperative infection (< 1 month after 
index surgery), late chronic infection (> 1 month after index surgery), acute hematog-
enous infection (antecedent bacteremia with acute onset of symptoms in affected joint 
with the prosthesis), or infection diagnosed from positive intraoperative cultures (≥ 2 
positive cultures of the same specimen obtained at the time of revision operation).
the study period—were censored. To compare 
treatment outcome in patients treated with and 
without rifampicin, log-rank analysis was used. 
All statistical analyses were done using IBM 
SPSS statistics version 20.0. Any p-value of 
less than 0.05 was considered to be statistically 
significant.
Ethics
Approval of the local ethics committee was 
obtained on January 22, 2014 (registration 
number 608).
Results
Patient characteristics
We included 60 patients. The characteristics of 
the 2 antimicrobial treatment groups, those with 
and without rifampicin combination therapy, 
did not differ statistically significantly from 
each other (Table 1). The clinical presentation 
prior to the diagnosis of Propionibacterium-
associated PJI consisted mainly of persistent 
joint pain (in 49 of the 60 patients) and joint 
stiffness (in 25 of the 60). About a quarter of 
patients had an elevated ESR and CRP. The 
median number of intraoperative tissue cul-
tures obtained was 6 (5–10) per patient with a 
median of 3 (2–9) positive cultures. In 57 of the 
60 patients, tissue cultures gave Propionibac-
terium acnes. The other 3 cases were caused 
by an unspecified Propionibacterium species. 
A monomicrobial infection was found in 47 
patients. In 11 of 13 patients, tissue cultures 
showed a polymicrobial infection with Propi-
onibacterium species and coagulase-negative 
staphylococci. 
Preoperatively, a small proportion of patients 
were suspected of having an infection (19/60). 
4 patients were diagnosed with an early post-
operative infection after primary joint arthro-
plasty. They presented with symptoms of an 
Acta Orthopaedica 2016; 87 (1): 60–66 63
Treatment
All patients were treated with a combination of surgery and a 
3-month postoperative antimicrobial regimen (Table 2). 
Surgical treatment
6 patients underwent debridement with prosthesis retention 
because of an early postoperative infection (4/6) or a hema-
togenous infection (2/6). 13 patients, suspected preoperatively 
of having a late chronic infection, underwent a two-stage 
exchange arthroplasty. 41 patients who were not suspected 
preoperatively of having an infection were diagnosed from 
positive intraoperative cultures and treated with a one-stage 
exchange arthroplasty, 10 of which had partial revision of 
the prosthesis, i.e. the femoral/humeral or acetabular/glenoid 
component. 
treatment failure. During the follow-up of 2 years, 7 failures 
occurred, 4 patients had a relapse infection with a Propi-
onibacterium species, and 3 patients had a reinfection with 
another pathogen. These 7 patients underwent revision sur-
gery in which the prosthesis was removed (Tables 3 and 4). 
Using the Kaplan-Meier method, an overall cumulative suc-
cess rate of 93% (95% CI: 83–97) after 1 year and 86% (CI: 
71–93) after 2 years was found (Figure 1). Patients treated 
without rifampicin combination therapy had a cumulative 
success rate of 90% (CI: 67–98) after 1 year and 82% (CI: 
53–94) after 2 years. A cumulative success rate of 95% (CI: 
81–99) and 88% (CI: 69–95) was reached in patients treated 
with rifampicin combination therapy after 1 year and 2 years, 
respectively (Figure 2). Comparison of the overall cumulative 
success rate of patients treated with and without rifampicin 
revealed a p-value of 0.7 (log-rank test).
Table 2. Surgical treatment and postoperative antimicrobial regimen in 60 patients with 
Propionibacterium-associated PJI, presented according to their postoperative antimicro-
bial treatment
Characteristic Rifampicin No rifampicin Total group p-value
 (n = 39) (n = 21) (n = 60) 
Surgical treatment    0.5
 Debridement and prosthesis retention   5   1   6 
 1-stage revision (partial revision) 25 (5) 16 (5) 41 (10) 
 2-stage revision   9   4 13 
Antibiotic treatment (daily doses)   
 Clindamycin 600 mg x 3 
    and rifampicin 450 mg x 2 33   – 33 
 Teicoplanin 400 mg x 1 i.v. 
    and rifampicin 450 mg x 2   6   –   6 
 Clindamycin 600 mg x 3   – 16 16 
 Amoxicillin 500 mg x 4   –   1   1 
 Ciprofloxacin 750 mg x 2 
    and clindamycin 600 mg x 3   –   1   1 
 Doxycycline 200 mg x 1   –   1   1 
 Linezolid 600 mg x 2   –   1   1 
 Teicoplanin 400 mg x 1 i.v.   –   1   1 
  
i.v.: intravenously.
Antimicrobial regimen
After antimicrobial treatment with 
cefazoline intravenously (1,000 mg 3 
times a day), a switch in antimicro-
bial treatment took place, guided by the 
positive intraoperative cultures. In all 
the patients included, low MICs were 
observed for clindamycin, penicillin, 
and rifampicin in the Propionibacte-
rium isolates tested (MIC < 0.5 mg/L). 
39 patients received a combination of 
antibiotics including rifampicin. 33 of 
these 39 patients received a combina-
tion of clindamycin (600 mg 3 times 
a day) and rifampicin (450 mg twice a 
day). 21 patients received antimicrobial 
treatment without rifampicin. 16 of 21 
patients received clindamycin only (600 
mg 3 times a day). In 25 patients, side 
effects of the antimicrobial regimen were 
reported, 16 of them in the group treated 
with rifampicin. Most side effects (22/25) 
were gastrointestinal symptoms, and 1 
patient with diarrhea was diagnosed with 
Clostridium difficile infection and treated 
with a course of metronidazole (500 mg 3 
times a day). All patients could continue 
their antibiotic treatment; in 7 cases, the 
dose of the antibiotic administered had to 
be diminished. Few patients (3/25) devel-
oped an allergic skin reaction. In these 
cases, there was a switch of antibiotic 
regimen. 
Outcome of treatment
60 patients were followed for at least 
1 year, with a median duration of 21 
(0.1–49) months until the occurrence of 
Table 3. Number and types of failures in 60 patients with Propionibacterium-associated 
PJI, presented according to their postoperative antimicrobial treatment
Characteristic Rifampicin No rifampicin Total group p-value
 (n = 39) (n = 21) (n = 60) 
Failures    
 1-year follow-up 2/39 2/21  4/60  0.7
 2-year follow-up 4/23 3/13 7/36  0.6
 Survival, median (range), months 19 (0.1–49) 23 (0.2–47) 21 (0.1–49) 0.9
Type of failure    
 Relapse a 2 2 4  0.4
 Reinfection b 2 1 3  0.5
a Relapse: defined as positive cultures growing the same microorganism as the initial intra-
operative samples.
b Reinfection: defined as a new infection with a pathogen other than that in the initial intra-
operative samples.
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Discussion
This retrospective cohort study was conducted to determine 
the success rates after treatment of Propionibacterium-associ-
ated PJI of the shoulder, hip, and knee at 1- and 2-year follow-
up. We also attempted to determine if there was a difference 
in treatment success in patients treated with or without rifam-
picin combination therapy. We found an overall cumulative 
success rate of 93% after 1-year follow-up and 86% after and 
2-year follow-up. Similar treatment success was found in 
patients who were treated with or without rifampicin combi-
nation therapy. 
The patient characteristics of our cohort are comparable to 
those in previous studies, and support the evidence that clini-
cal findings before the diagnosis of Propionibacterium-asso-
ciated PJI are subtle (Zappe et al. 2008, Dodson et al. 2010). 
Furthermore, the success rates we observed are in line with 
the few published data. Zeller et al. (2007) found a success 
rate after 2-year follow-up of 92% in 48 patients who were 
treated for Propionibacterium-associated PJI. All of these 48 
patients underwent surgery and underwent long-term antibi-
otic treatment. Most of these patients received an antibiotic 
regimen of cefalosporines and rifampicin or clindamycin and 
rifampicin. A smaller study by Levy et al. (2008) found favor-
Table 4. Overview of the patient characteristics of 7 failed cases treated for Propionibacterium-associated PJI
        Change in  Duration 
   Location Preoperative Micro- PJI classi- Antibiotic antibiotic  of survival Type of
Case Age Sex of joint diagnosis organism(s) fication a treatment treatment Surgery (months) failure
1 51 M Shoulder Suspected P. acnes Late chronic Clindamycin No 2-stage revision 0.2 Relapse
    infection
2 72 F Shoulder Dysfunction P. acnes PIOC Clindamycin No 1-stage revision 19 Reinfection
       + rifampicin  (total revision)
3 56 M Knee Dysfunction P. acnes PIOC Clindamycin No 1-stage revision 0.1 Reinfection
       + rifampicin  (total revision)
4 40 F Hip Aseptic P. acnes PIOC Clindamycin No 1-stage revision   7 Relapse
    loosening   + rifampicin  (partial revision)
5 78 M Shoulder Suspected P. acnes Late chronic Clindamycin No 2-stage revision 14 Relapse
    infection   + rifampicin
6 50 M Hip Suspected P. acnes +  Early postop. Clindamycin Yes b Debridement and 0.1 Reinfection
    infection Morganelli  + ciprofloxacin  prosthesis retention
     morganii  
7 56 M Shoulder Dysfunction P. acnes PIOC Clindamycin No 1-stage revision 23 Relapse
         (total revision)
a According to Tsukayama et al. (1996), see Table 1. PIOC: Positive intraoperative cultures
b
 Ciprofloxacin dose was reduced because of adverse effects.
Figure 1. Kaplan-Meier survival curve of 60 patients treated for Propi-
onibacterium-associated PJI. The cumulative success rate was 93% 
(95% CI: 83–97) and 86% (95% CI: 71–93) after 1 year and 2 years, 
respectively. The small vertical spikes represent the censored data.
Figure 2. Comparison of Kaplan-Meier survival curves of patients 
treated for Propionibacterium-associated PJI with and without rifam-
picin combination therapy. A cumulative success rate of 90% (95% CI: 
67–98) and 82% (95% CI: 53–94) was found in patients treated without 
rifampicin after 1 year and 2 years, respectively. A cumulative success 
rate of 95% (95% CI: 81–99) after 1 year and 88% (95% CI: 69–95) 
after 2 year was reached in patients treated with rifampicin. Overall 
comparison of the cumulative success rates revealed a p-value of 0.7 
(log-rank test). The small vertical spikes represent the censored data.
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able results from combination therapy with amoxicillin and 
rifampicin. 
Unexpectedly, we did not find a higher success rate in 
patients treated with rifampicin combination therapy, despite 
the established effectiveness of rifampicin in staphylococcal 
PJI (Zimmerli et al. 1998, Baldoni et al. 2009, John et al. 
2009, El Helou et al. 2010) and the successful eradication 
of Propionibacterium biofilms with rifampicin in in-vitro 
studies (Bayston et al. 2007b, Furustrand Tafin et al. 2012) 
and in-vivo studies (Furustrand Tafin et al. 2012). Our study 
results can be explained in several ways. First of all, most 
of our patients underwent surgical treatment consisting of 
exchange arthroplasty in combination with long-term post-
operative antimicrobial treatment with or without rifampicin. 
Studies researching the effect of additional rifampicin in the 
treatment of staphylococcal PJI were performed in patients 
undergoing debridement and retention of the prosthesis (Zim-
merli et al. 1998, El Helou et al. 2010). Since rifampicin is 
known to be a biofilm-active antibiotic, the additional ben-
efit when the infected prosthesis has already been removed 
is debatable. Secondly, most of our patients who received 
rifampicin were treated with a combination of clindamycin 
and rifampicin. Several authors have described a decrease in 
clindamycin plasma concentration, which is influenced by 
co-administration of rifampicin (Zeller et al. 2010, Bouazza 
et al. 2012, Join-Lambert et al. 2014, Curis et al. 2015), pre-
sumably because rifampicin is a potent inducer of hepatic 
cytochrome P-450 3A4 (Niemi et al. 2003), the main met-
abolic pathway of clindamycin (Wynalda et al. 2003). This 
could result in a less than optimal treatment. Still, it is uncer-
tain whether this conflicting interaction between clindamy-
cin and rifampicin is of clinical relevance, because several 
in-vitro, in-vivo, and clinical data show good effectiveness 
of clindamycin and rifampicin combination therapy against 
Staphylococcus-related osteoarticular infections (Arditi and 
Yogev 1989, O’Reilly et al. 1992, Zeller et al. 2010, Czekaj 
et al. 2011, Curis et al. 2015). 
Our study had some limitations. First, the historical study 
design and the use of data not primarily intended for research 
resulted in bias from missing data. Patients were only included 
in the analyses if there was a minimum follow-up of 1 year, 
and notes were present in the patients’ medical records which 
may have contributed to selection bias and given an overes-
timation or underestimation of the success rates calculated. 
Another shortcoming, and contributory factor to selection bias, 
was the choice of antibiotic treatment with or without rifam-
picin, which was based on personal preference. No predefined 
criteria were used to substantiate the choice of whether or 
not a patient should receive rifampicin combination therapy. 
Furthermore, we included a small and heterogeneous group 
of patients with different types of PJIs of the knee, hip, and 
shoulder, which were treated with different types of surgery 
and antimicrobial treatment regimens. This would have con-
tributed to a lack of power and increased the probability of 
type-2 error. A possible difference in success rates between 
the 2 treatment groups could be missed. It could also be that 
the null hypothesis was correct and that there was no differ-
ence in success rates between the 2 treatment groups. 
In summary, to our knowledge this is the first clinical study 
to compare antibiotic treatment regimens in Propionibacte-
rium-associated PJI. A combination of surgery and long-term 
antibiotic treatment postoperatively resulted in an overall suc-
cess rate of 93% at 1-year follow-up and 86% at 2-year follow-
up. No significant difference in treatment success was found 
between patients treated with rifampicin combination therapy 
and those treated without. Prospective studies are required to 
determine the benefit of adding rifampicin for the treatment of 
Propionibacterium-associated PJI. 
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